A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
NCT ID: NCT01044342
Last Updated: 2010-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2009-12-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
NCT01125683
A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People
NCT06367426
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
NCT02051335
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
NCT01039701
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Single dose of AZD1446 10 mg
AZD1446
capsule; single oral dose
B
Single dose of AZD1446 80 mg
AZD1446
capsule, single oral dose
C
Single Dose of Donepezil 5 mg
donepezil
capsule, single oral dose
D
Single dose of placebo to match AZD1446
Placebo
capsule, single oral dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1446
capsule; single oral dose
AZD1446
capsule, single oral dose
donepezil
capsule, single oral dose
Placebo
capsule, single oral dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smoker for at least 4 weeks
Exclusion Criteria
* Hypersensitivity to scopolamine
* History of substance abuse
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Rouffach, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2285M00021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.